Molecular-based diagnosis of multiple sclerosis and its progressive stage.

ABSTRACT:

Objective

Biomarkers aid diagnosis, allow inexpensive screening of therapies, and guide selection of patient-specific therapeutic regimens in most internal medicine disciplines. In contrast, neurology lacks validated measurements of the physiological status, or dysfunction(s) of cells of the central nervous system (CNS). Accordingly, patients with chronic neurological diseases are often treated with a single disease-modifying therapy without understanding patient-specific drivers of disability. Therefore, using multiple sclerosis (MS) as an example of a complex polygenic neurological disease, we sought to determine whether cerebrospinal fluid (CSF) biomarkers are intraindividually stable, cell type-, disease- and/or process-specific, and responsive to therapeutic intervention.

M

SUBMITTER: Barbour C 

PROVIDER: S-EPMC5743213 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature